Dr. Hugo López-Gatell, Undersecretary of Prevention and Health Promotion, reported this Friday that the evaluation process of the Pfizer-BioNTech vaccine by the Federal Commission for the Protection against Sanitary Risks (COFEPRIS) concluded.
This means that Mexico would become the fourth country to authorize the emergency use of the COVID-19 vaccine from these pharmaceutical companies.
This is what the official said during the conference on the advance of the pandemic in the country, from the National Palace:
The good news is that the evaluation process has concluded (…). The signal is one of hope and encouragement because it brings us closer to the start of vaccination in Mexico.
He clarified that so far, three countries have already given their authorization: the United Kingdom, Canada, and Bahrain, pending approval in the United States by the Food and Drug Administration (FDA, for its acronym in English).
COFEPRIS is a decentralized body dependent on the Ministry of Health (Ssa), which has the responsibility of authorizing health supplies, such as medicines and vaccines.
Since last November 26, it has reviewed, evaluated, and ruled the documentation submitted for the sanitary authorization of the Pfizer-BioNTech COVID-19 vaccine. However, until December 11, the 24 members of the Committee for New Molecules voted unanimously for its emergency use, according to a statement issued this Friday afternoon.
The Pfizer-BioNTech vaccine is messenger RNA (mRNA); that is, messenger RNA carrying a copy of genetic instructions is administered to the patient. With these instructions, the patient’s own body makes a part of the COVID-19 protein, thus causing a reaction of the immune system.